• UPDATE : 2020.1.20 월 18:34
상단여백
기사 (전체 66건)
Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events
Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is...
라인
European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the Committee for Medicinal Products for Human Us...
라인
Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer
Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement f...
라인
라인
Efficacy Results of Otsuka’s Delamanid (Deltyba) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that data from a post-hoc subset analysis of its Phase IIb clin...
라인
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care New resea...
라인
Hakim Djaballah, CEO of Institut Pasteur Korea, responds to comments made on the current MERS-CoV situation in Korea
Hakim Djaballah, CEO of Institut Pasteur Korea, responds to comments made on the current MERS-CoV situation in Korea. Pa...
라인
라인
Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Co...
라인
Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
DARMSTADT, GERMANY & NEW YORK--(Business Wire/Korea Newswire) May 14, 2015 -- Merck and Pfizer today announced multiple ...
라인
Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders
Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer ...
라인
라인
the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
CAMBRIDGE, MASS. & OSAKA, JAPAN--(Business Wire/Korea Newswire) February 10, 2015 -- Takeda Pharmaceutical Company Limit...
라인
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim announced today that it has established a research alliance with Vanderbilt University and the canc...
라인
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source
Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investi...
라인
라인
New data show specific antidote idarucizumab reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
For Non-US/Non-UK/Non-Canadian Media New data demonstrate that a five-minute infusion of the investigational specific an...
라인
Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Merck (MRK GY) (FWB:MRK) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-d...
라인
Takeda’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food & Drug Administration (FDA) has gran...
라인
KOHI successfully concluded 'Competency Enhancement of Diagnosis and Treatment of Autism Spectrum Disorder for child in Bangladesh' Program With KOICA
Korea Human Resource Development Institute for Health and Welfare, KOHI (Pr...
라인
Litigation Judgment Removes A Major Hurdle For Esomeprazole Strontium Delayed-release Capsules, Korea's First Domestically Developed 505(b)(2) NDA Drug Product
Hanmi Pharmaceutical Company Limited announced today that, pursuant to a confidential settlement agreement, a consent ju...
라인
OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and Second-Line Treatment for Patients With ROS1-Positive Non-Small Cell Lung Cancer
OxOnc Development LP, (OxOnc), today announced that it has entered into a co-development agreement with Pfizer Inc., to ...
라인
KOHI successfully concluded 'Maternal and Child Health Promotion Program for Latin America'
Korea Human Resource Development Institute for Health and Welfare, KOHI (Pr...
라인
Working with Asian countries to improve information-sharing in food safety emergencies
The World Health Organization (WHO) and the Food and Agriculture Organization of the United Nations (FAO) are working wi...
Back to Top